New drug shows promise for Hard-to-Treat blood cancer

NCT ID NCT05228470

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the disease for a period of time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Elranatamab (a drug that helps the immune system attack cancer cells)

What this could lead to

If successful, elranatamab could offer a new treatment option for Chinese patients with multiple myeloma that has stopped responding to other therapies.

What could go wrong

This is an early-phase trial with only 39 participants, so results may not apply to everyone. The drug can cause serious side effects like low blood cell counts and cytokine release syndrome.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Blood Protein Disorders cardiovascular disorder hematologic disorder hemorrhagic disease immune system disorder immunoproliferative disorder lymphoproliferative syndrome monoclonal gammopathy neoplasm Neoplasms by Histologic Type plasma cell myeloma plasma cell neoplasm refractory plasma cell neoplasm vascular disorder vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCMA BCMA-CD3 BISPECIFIC BISPECIFIC BISPECIFIC ANTIBODY ELRANATAMAB MAGNETISMM-8 MULTIPLE MYELOMA MYELOMA PF-06863135 REFRACTORY MULTIPLE MYELOMA RELAPSED MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Beijing Gaobo Boren Hospital

Beijing, 100070, China
Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China
Harbin First Hospital

Harbin, Heilongjiang, 150010, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, 300020, China
Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, 510515, China
Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, 210008, China
Peking Union Medical College Hospital

Beijing, 100730, China
Peking University Third Hospital

Beijing, 100191, China
Shandong Provincial Hospital

Jinan, Shandong, 250021, China
Shenzhen Second People's Hosptial

Shenzhen, Guangdong, 518035, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510555, China
The First Affiliated Hospital of College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China
The First Hospital of Jilin University

Changchun, Jilin, 130021, China